Antonio Mura

Antonio Mura

Auto-generated profile, based on publicly available information

Antonio Mura

Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy (F.B., A.M., M.P., M.G.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
GRGiulia Ruozi
Giulia Ruozi
FBFrancesca Bortolotti
Francesca Bortolotti
AMAntonio Mura
Antonio Mura
MTMateusz Tomczyk
Mateusz Tomczyk
AFAntonella Falcione
Antonella Falcione
MGMauro Giacca
Mauro Giacca
Therapies for patients with myocardial infarction and heart failure are urgently needed, in light of the breadth of these conditions and lack of curative treatments. To systematically identify previously unidentified cardioactive biologicals in an unbiased manner in vivo, we developed cardiac FunSel, a method for the systematic, functional selection of effective factors using a library of 1198 barcoded adeno-associated virus (AAV) vectors encoding for the mouse secretome. By pooled vector injection into the heart, this library was screened to functionally select for factors that confer cardioprotection against myocardial infarction. After two rounds of iterative selection in mice, cardiac FunSel identified three proteins [chordin-like 1 (Chrdl1), family with sequence similarity 3 member C (Fam3c), and Fam3b] that preserve cardiomyocyte viability, sustain cardiac function, and prevent pathological remodeling. In particular, Chrdl1 exerted its protective activity by binding and inhibiting extracellular bone morphogenetic protein 4 (BMP4), which resulted in protection against cardiomyocyte death and induction of autophagy in cardiomyocytes after myocardial infarction. Chrdl1 also inhibited fibrosis and maladaptive cardiac remodeling by binding transforming growth factor–β (TGF-β) and preventing cardiac fibroblast differentiation into myofibroblasts. Production of secreted and circulating Chrdl1, Fam3c, and Fam3b from the liver also protected the heart from myocardial infarction, thus supporting the use of the three proteins as recombinant factors. Together, these findings disclose a powerful method for the in vivo, unbiased selection of tissue-protective factors and describe potential cardiac therapeutics.

2 December 2025 in Circulation
Verified
Journal Article
Closed access
MTMateusz Tomczyk
Mateusz Tomczyk
IKIzabela Kraszewska
Izabela Kraszewska
GLGang Li
Gang Li
MHMatthew Hayes
Matthew Hayes
LVLuca Venditti
Luca Venditti
MGMauro Giacca
Mauro Giacca